Last reviewed · How we verify

JOBEVNE (BEVACIZUMAB-NWGD)

BIOCON BIOLOGICS INC · FDA-approved approved Quality 6/100

JOBEVNE (generic name: BEVACIZUMAB-NWGD) is a Vascular Endothelial Growth Factor Inhibitor [EPC] drug developed by BIOCON BIOLOGICS INC. It is currently FDA-approved.

At a glance

Generic nameBEVACIZUMAB-NWGD
SponsorBIOCON BIOLOGICS INC
Drug classVascular Endothelial Growth Factor Inhibitor [EPC]
Therapeutic areaOther
PhaseFDA-approved

Approved indications

No approved indications tracked.

Common side effects

Serious adverse events

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about JOBEVNE

What is JOBEVNE?

JOBEVNE (BEVACIZUMAB-NWGD) is a Vascular Endothelial Growth Factor Inhibitor [EPC] drug developed by BIOCON BIOLOGICS INC.

Who makes JOBEVNE?

JOBEVNE is developed and marketed by BIOCON BIOLOGICS INC (see full BIOCON BIOLOGICS INC pipeline at /company/biocon-biologics-inc).

What is the generic name of JOBEVNE?

BEVACIZUMAB-NWGD is the generic (nonproprietary) name of JOBEVNE.

What drug class is JOBEVNE in?

JOBEVNE belongs to the Vascular Endothelial Growth Factor Inhibitor [EPC] class. See all Vascular Endothelial Growth Factor Inhibitor [EPC] drugs at /class/vascular-endothelial-growth-factor-inhibitor-epc.

What development phase is JOBEVNE in?

JOBEVNE is FDA-approved (marketed).

What are the side effects of JOBEVNE?

Common side effects of JOBEVNE include Leukopenia, Diarrhea, Fatigue, Neutropenia, Sensory neuropathy, Diarrhea. Serious adverse events: Hemorrhage, Intra-abdominal thrombosis, Syncope, Ileus.

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing